Position in NGEN
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$64,684
-$53,694 QoQ
Shares Held
31,400
0.0% QoQ
Ownership
0.029%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#29
of 62 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NGEN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cetera Investment Advisers holds $187,106,390 across 112 Biotechnology names. NGEN ranks #84 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
78,107 | $38,798,090 | |
| 2 | IBRX |
ImmunityBio, Inc.
|
1,140,476 | $9,984,867 | |
| 3 | EXEL |
Exelixis, Inc.
|
169,657 | $9,231,037 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
14,664 | $9,143,590 | |
| 5 | OCUL |
Ocular Therapeutix, Inc
|
785,732 | $7,715,888 | |
| 6 | ARGX |
Argenx SE
|
7,844 | $7,277,427 | |
| 7 | VKTX |
Viking Therapeutics, Inc.
|
184,543 | $7,199,022 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
23,196 | $6,982,691 |
All Filings in NGEN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $64,684 | 31,400 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $118,378 | 31,400 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||